A prospective randomized joint study was conducted to evaluate the usefulness of UFT 1) as a postoperative adjuvant
therapy in patients with invasive
bladder cancer who had undergone curative combination
therapy with operation and/or
chemotherapy and/or
radiation therapy, 2) as an endocrine
chemotherapy in patients with newly diagnosed stage C/D
prostate cancer, for a period of 3 years from January, 1992. For
bladder cancer, of 36 patients with invasive
bladder cancer, clinically cured by combination
therapy, 20 patients were treated with UFT as an
adjuvant chemotherapy over 12 months, and they were compared to 16 patients with no adjuvant
therapy. After excluding 10 inappropriate patients, 12 patients in the UFT treatment group and 14 patients with no adjuvant treatment group were observed. For
prostate cancer, of 29 patients with clinically stage C/D
prostate cancer, 13 were treated with endocrine
therapy in combination with UFT, and 16 patients were treated with endocrine
therapy alone. After excluding 7 inappropriate patients, 10 patients with endocrine
chemotherapy and 12 patients with hormonal
therapy were observed. The non-recurrence rate, survival rate and side effects of UFT were evaluated. In the study of
bladder cancer, neither a significant difference of non-recurrent rate nor of survival rate was seen between the two groups. In the study of
prostate cancer, neither a significant difference of non-recurrent rate nor of survival rate was seen between the two groups. These findings suggest UFT is less useful as an adjuvant
therapy for the invasive
bladder cancer and as an endocrine
chemotherapy for newly diagnosed advanced
prostate cancer.